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The renin-angiotensin system (RAS) is a critical regulator of hypertension, primarily through the actions of the vasoactive peptide
Ang II, which is generated by the action of angiotensin-converting enzyme (ACE) mediating an increase in blood pressure. The
discovery of ACE2, which primarily metabolises Ang II into the vasodilatory Ang-(1-7), has added a new dimension to the
traditional RAS. As a result there has been huge interest in ACE2 over the past decade as a potential therapeutic for lowering
blood pressure, especially elevation resulting from excess Ang II. Studies focusing on ACE2 have helped to reveal other actions of
Ang-(1-7), outside vasodilation, such as antiﬁbrotic and antiproliferative eﬀects. Moreover, investigations focusing on ACE2 have
revealed a variety of roles not just catalytic but also as a viral receptor and amino acid transporter. This paper focuses on what
is known about ACE2 and its biological roles, paying particular attention to the regulation of ACE2 expression. In light of the
entrance of human recombinant ACE2 into clinical trials, we discuss the potential use of ACE2 as a therapeutic and highlight some
pertinent questions that still remain unanswered about ACE2.
1.Introduction
When angiotensin-converting enzyme-2 (ACE2) was seren-
dipitously discovered ten years ago, neither of the two groups
at the centre of its discovery [1, 2] could have guessed at
the disproportionate number of distinct roles it plays in
biology, from cardiovascular regulation to viral infection.
As so often happens in modern biological research two
independentapproachesconvergedonthesamediscovery,to
give us ACE2 or angiotensin-converting enzyme homologue
(ACEH),backin2000.Overthepasttenyearsourknowledge
of this protein’s role in the body has increased exponentially,
resultinginrecombinantACE2proteinenteringclinicaltrials
back in 2009. This paper will focus on what we currently
know about ACE2 and its regulation, highlighting some of
thegapsanddiscrepanciesthatstillremaininourknowledge.
2. Biochemistry andCell Biology of ACE2:
Comparisons andDistinctions from ACE
ACE inhibitors have been the ﬁrst line of treatment against
hypertension for decades, and their success has served to
place ACE and its biologically active product, angiotensin
II (Ang II), as central regulators of the renin-angiotensin
system (RAS). Ang II is produced by ACE through hydrolysis
of its precursor Ang I. Ang II is the major vasoactive peptide
in the RAS, acting as a potent vasoconstrictor through its
receptor AT1R (Figure 1). Hence, inhibition of the produc-
tion of Ang II and more recently its receptor-induced sig-
nalling, through the use of AT1R blockers, have been highly
successful treatments in hypertension. Consequently there
was immediate commercial interest in ACE2, as another
likely therapeutic target, when it was discovered as an active
homologue of ACE. However, as the initial publications
observed to their surprise, despite high similarity to ACE
(Figure 2), ACE2 did not convert Ang I to Ang II nor was
it inhibited by ACE inhibitors [1, 2]. A major diﬀerence in
substrate speciﬁcity was immediately noticed, namely, that
ACE2 acted as a carboxypeptidase removing a single amino
acid from the C-terminus of susceptible substrates whereas
ACE acts as a carboxy-dipeptidase (more correctly, peptidyl-
dipeptidase), removing a C-terminal dipeptide. ACE2 does
hydrolyse the decapeptide Ang I, albeit relatively poorly, but
converts it to Ang-(1-9) rather than Ang II (Ang-(1-8)).2 International Journal of Hypertension
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Figure 1: Schematic representation of the renin-angiotensin system (RAS). ACE: angiotensin-converting enzyme; ACE2: angiotensin-
converting enzyme 2; NEP: neprilysin; AT1R: Ang II type 1 receptor. Angiotensinogen is cleaved by renin in the circulation to generate
Ang I. Ang I is cleaved to yield Ang II by ACE, Ang-(1-7) by NEP, or Ang (1-9) by ACE2; this reaction is much less favourable than the
production of Ang-(1-7) from Ang II. Ang-(1-9) is then cleaved by either NEP or ACE to yield Ang-(1-7) in a minor pathway. Ang II exerts
its main actions by binding to the AT1R. Ang II can also be further cleaved by ACE2, into Ang-(1-7), which exerts its eﬀects through its
receptor (Mas). The opposing actions of the two receptors are listed above.
It was initially hypothesised that ACE2 counterbalanced the
actions of ACE as Ang-(1-9) is also metabolised by ACE
and therefore competes with Ang I for its active site, thus
providing a novel regulatory arm to the RAS (Figure 1).
StudiesrevealedthatACE2hydrolysesanumberofsubstrates
[3] and preferentially cleaves terminal amino acids from
peptides ending in Pro-X, where X is a hydrophobic amino
acid [4]. The hydrolysis of some ACE2 substrates is chloride-
dependent, as is the case for ACE, and the structural basis
for this selectivity has been proposed [5]. Of the biologically
active peptides that ACE2 cleaves, the most relevant are
apelin-13 [6]a n dA n gI I[ 3] .I no r d e rt of u r t h e ru n d e r s t a n d
the biological relevance of ACE2 an inhibitor was developed
based on the C-terminal dipeptide (His-Leu) of Ang I. This
allowed development of the potent and speciﬁc inhibitor,
MLN-4760 [4], which has been used in numerous studies of
ACE2 action in vivo and in vitro, although the compound is
not currently commercially available.
The elucidation of the structure of ACE2, and subse-
quent comparative modelling studies, explained its distinct
speciﬁcity by revealing subtle diﬀerences in the active sites
of ACE and ACE2 [7–10]. A single amino acid substitution
in ACE2 sterically hinders the entrance of the penultimate
substrate amino acid into the active site, thereby eliminating
the ACE-like peptidyl-dipeptidase activity [7]. The substrate
speciﬁcity of ACE2 was clariﬁed when it was shown that
ACE2 had a much higher catalytic eﬃciency for hydrolysis of
Ang II (400-fold) compared with Ang I [3]. Only under con-
ditions of elevated Ang I concentrations (such as in patients
on ACE inhibitor therapy) is the conversion of Ang I to Ang-
(1-9) by ACE2 (Figure 1.) likely to be of any physiological
signiﬁcance [11]. The revelation that the main product of
the catalytic activity of ACE2 was Ang-(1-7) (Figure 1),
a vasodilatory peptide, led to a complete reevaluation of
its therapeutic potential. Currently strategies are aimed at
upregulation of ACE2 expression and activity, technically
more complex than enzyme inhibition. This does not rule
out any potential application of ACE2 inhibitors which have
recently been proposed as possible anti-inﬂammatories [12],
having initially but unsuccessfully been tested as potential
antiobesity drugs.
The main tissue sites of expression of ACE2 were
originally identiﬁed as testis, heart, and kidney [1], where
it was shown to be localised on the apical membrane of
polarised cells whereas ACE is equally distributed between
apical and basolateral membranes [13]. The molecular basis
for this diﬀerential localization has not been addressed
but presumably relates to determinants in the C-terminalInternational Journal of Hypertension 3
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Figure 2: The domain structure and membrane topology of somatic ACE, ACE2, and collectrin. Each protein is a type I integral-membrane
protein with an N-terminal ectodomain, a transmembrane region, and a short C-terminal cytoplasmic tail. Residue numbers are indicated.
Both ACE and ACE2 contain zinc-binding motifs (HEMGH), which form the active sites of the enzyme: somatic ACE has two active sites
whereas ACE2 only has one. Collectrin contains no catalytic residues. ACE2 is homologous to the N-terminal ectodomain of ACE but has
no homology with its C-terminal cytoplasmic domain. Instead, it shares a number of residues with the intracellular domain of collectrin.
Signal peptide in light grey; transmembrane domain in textured grey.
cytoplasmic tails of the two enzymes which are quite distinct
in sequence. The tissue distribution of ACE2 has now been
catalogued more widely, for example, in liver, intestine,
and lung [14, 15]. More recently ACE2 has been localized
in the brain [16], where it appears to act as a central
regulator of cardiovascular function [17–20]. ACE2 is a type
1 transmembrane protein (N-terminus outside, C-terminus
intracellular), predominantly localised on endothelial cells
where its catalytic site, like that of ACE, is exposed (so-called
“ectoenzyme”) to circulating vasoactive peptides [13]. The
activity of ACE2 can therefore be modulated via its expres-
sion on the cell surface, through its expression levels and also
through its cleavage from the cell membrane. This cleavage
or shedding releases the catalytically active ectodomain and
when stimulated, for example, by phorbol esters, is mediated
by a disintegrin and metalloprotease (ADAM 17) [21]. ACE
also undergoes constitutive and regulated shedding from the
cell surface into plasma although the enzymes responsible in
t h i sc a s eh a v en o tb e e ni d e n t i ﬁ e d .
3.ACE2andCardiovascularFunction
The success of ACE inhibitors has shown that Ang II is a key
mediatorofhypertension,and,hence,bymetabolisingAngII
into Ang-(1-7), ACE2 is crucial in the modulation of blood
pressure.The roleofACE2 inhypertensionhas beenclariﬁed
by its overexpression in vivo, reducing blood pressure
in hypertensive models [22–24] but not in normotensive
animals [25]. This reduction in blood pressure may be the
result of increased sensitivity of the baroreﬂex, which has
been seen upon ACE2 delivery in hypertensive models [26],
andareductioninneuronallyinducedhypertensionhasbeen
observed in transgenic mice [19]. Central blood pressure
r e g u l a t i o ni sc o n t r o l l e di np a r tb yt h ea c t i o n so fA n gI Io n
the AT1R. Ang II acts through the AT1R to desensitise the
baroreﬂex, stimulate water uptake, and increase vasopressin
release and sympathetic activation, ultimately leading to
increased blood pressure [27]. The actions of Ang II are
in part modulated by the increase in baroreﬂex sensitivity
mediatedbyAng-(1-7)[28,29].Comparisonofhypertensive
models to normotensive rodents has revealed decreased
ACE2 protein expression by up to 40%, in the brain, of the
hypertensive models [20, 22]. Moreover, overexpression of
ACE2 in the brain attenuates hypertension, via an increase
in nitric oxide production [19] and improved baroreﬂex
[20]. Accordingly, injection of the ACE2 inhibitor MLN-
4760 into the brain of rodents attenuates the baroreﬂex [18].
Site-speciﬁc overexpression of ACE2 at a locus controlling4 International Journal of Hypertension
sympathetic nerve activity reduces the overall hypertensive
state of rats [22]. For a review of the roles of ACE2 in central
blood pressure regulation, see [30].
Soon after its discovery, gene deletion studies established
ACE2 not only as a modulator of blood pressure but also as
an essential regulator of cardiovascular function [31]. The
progressive cardiac dysfunction observed in the ﬁrst ACE2
mouse knockout model resembled that of tissue subjected
to long-term hypoxia of the type that occurs after coronary
artery disease or bypass surgery in humans [32]. As a result
of these observations ACE2 was immediately proposed as a
cardioprotective protein. This hypothesis was strengthened
by the observation that ACE2-null phenotypes were reversed
by concurrent knockout of the ACE gene. This evidence
appeared to demonstrate unequivocally that the primary
role of ACE2 was to counterbalance that of ACE [31]. The
initial hypothesis that ACE2 plays a critical role in cardiac
function primarily by counterbalancing the eﬀects of ACE
was not, however, entirely supported by subsequent gene
deletion models. The discrepancies between the initial study
and the phenotypes are described elsewhere, which saw no
obvious functional or morphological changes [33, 34], were
initially proposed to be due to diﬀering genetic backgrounds
in their models. This potential mechanism was investigated
by backcrossing the hybrid model used in both studies with
an initial parental line; however, both backcrossed models
showed no cardiac changes [34]. Interestingly subsequent
studies using the original ACE2-deﬁcient mice described
by Crackower et al. also showed no overt cardiac changes,
suggesting that the phenotype is lost over time [35, 36].
Despite seeing no overt phenotypic change in deletion
models, subsequent groups have shown a reduced ability to
respond to injury in ACE2-null mice. Together these studies
suggest that, rather than being a key mediator of cardiac
phenotype, ACE2 is essential in modulating responses to
injury [33, 37].
In fact ACE2 deletion models have a signiﬁcantly higher
mortality rate after myocardial infarction (MI) than wild-
type mice, associated with adverse ventricular remodelling
and worsening ventricular function following MI [38]. An
increase in matrix metalloproteinase2 (MMP2) and MMP9
activation, free radical production, and upregulation of
proinﬂammatory cytokines, in the hearts of ACE2-knockout
mice, were postulated to mediate the adverse remodelling
after MI. These events, and the adverse remodelling they
cause, were reversed upon administration of an AT1R
blocker, and therefore the pathology of ACE2 deletion in
states of injury can be attributed, for the most part, to
increases in the local levels of Ang II [38].
The ability of ACE2 to improve responses to injury is
not only the result of clearing Ang II, thereby limiting its
pathological potential, but also by producing Ang-(1-7). The
conversion of Ang II to Ang-(1-7) by ACE2 is not the only
physiological route to Ang-(1-7) production. For example,
the zinc metallopeptidase neprilysin (NEP) can convert Ang
I to Ang-(1-7) eﬃciently [39], and both ACE and NEP can
convert Ang-(1-9) to Ang-(1-7). The relative importance of
these various enzymes to Ang-(1-7) production will vary
dependent on their relative expression levels in diﬀerent
tissues (e.g., kidney versus heart versus brain) and on
physiological status. Like Ang II the actions of Ang-(1-
7) extend beyond vasopressor control. Infusion of Ang-(1-
7) reduces interstitial ﬁbrosis in Ang II-independent [40]
and Ang II-dependent hypertension [41]. Interestingly in
both studies there was no eﬀect on the blood pressure
of hypertensive animals when infused with chronic levels
of Ang-(1-7). There was, however, a discrepancy in the
eﬀects of Ang-(1-7) on cardiac hypertrophy between the
two studies. Ang-(1-7) had no eﬀect on the salt-induced
hypertrophy in Ang II-independent hypertension but it sig-
niﬁcantly reduced myocyte hypertrophy in Ang II-induced
hypertension. Cardiac-speciﬁc overexpression of Ang-(1-7)
was observed to reduce the hypertrophic response to Ang II
concurrentlywithareductioninhypertrophicmarkers,atrial
natriuretic peptide and brain natriuretic peptide, transcript
levels and activation of hypertrophic signalling pathways, c-
src and p38 MAPK [42]. Ang-(1-7) inhibits myocyte cell
growth in vitro through the actions of the MAS receptor
[43] and accordingly prevents ventricular hypertrophy in
vivo, when stimulated by myocardial infarction (MI) [44].
The reduction in myocyte diameter and ventricular weight
of mice virally expressing Ang-(1-7) was associated with
a decrease in proinﬂammatory cytokines (TNFα and IL-6)
compared to control. It is worth noting that Ang-(1-7)
overexpressionslightlyreducedexogenousACEmRNAlevels
and ablated the approximate twofold increase in expression
resulting from MI, whilst increasing ACE2 expression levels
in response to MI [44].
ACE2 levels have consistently been shown to alter in
cardiovascular disease states. In light of the counterbalanc-
ing hypothesis it could be presumed that, since ACE is
consistently reported to increase in damaged cardiac tissue
[45–47], ACE2 levels would also increase as a homeostatic
response to oﬀset the rise in Ang II concentration. This
hypothetical upregulation is supported by evidence from
human nonischaemic cardiomyopathy, which has consis-
tently shown increased ACE2 levels in the failing human
heart compared to control patients [48–50]. However, in
contrast, in ischaemic cardiomyopathy, there is currently
conﬂicting evidence for the changes in expression levels of
ACE2 [48, 49]. Where ACE2 upregulation has been seen
in these studies, the mechanism of this damage-induced
increase has been investigated using in vivo models of MI.
ACE2 upregulation has been repeatedly shown in rat models
of MI [38, 51, 52]. Discrepancies between the mRNA and
protein levels seen in the infarct zone have suggested that the
increaseinACE2proteinismediatedbyaposttranscriptional
mechanism [38]. However, time-course investigations reveal
that the increases seen at eight weeks after MI were followed
by a decrease in ACE2 expression in MI models compared to
control after 28 weeks [52]. Although not entirely consistent
theseresultsonbalanceseemtoindicateacompensatoryrole
for ACE2 in conditions of myocardial injury.
Given its role in removing Ang II, ACE2 was identiﬁed as
a candidate gene underlying the loci linked to hypertension
[31], following its initial mapping to the X chromosome
[1]. Comparison of ACE2 expression levels in the kidneys
of three rat strains showed that ACE2 expression wasInternational Journal of Hypertension 5
lower in the hypertensive-prone strains and moreover that
ACE2 expression decreased signiﬁcantly when hypertension
was initiated in salt-sensitive hypertensive rats. Decreased
endogenous ACE2 expression has been noted in sponta-
neously hypertensive rats compared to Wistar-Kyoto [53].
The initial study did not see any genetic changes associated
with the ACE2 gene in these hypertensive strains, supporting
subsequentdata,whichhave,upuntilnow,failedtoshowany
link between ACE2 polymorphisms and hypertension [54].
4.ACE2,theKidney, andDiabetes
ACE2 is abundantly expressed in the kidneys, where its
expression is inversely correlated with hypertension [55,
56]. The local RAS within the kidneys is activated by
hyperglycemic conditions, which model the environment in
type 2 diabetes [57]. Studies using models of type 2 diabetes
have shown at early stages, prior to diabetic nephropathy
developing, that ACE2 expression is reduced in the kidney,
while ACE expression is elevated [58]. Similarly in models
of type 1 diabetes ACE2 expression is elevated in early
[59] and decreased in late stage of diabetic nephropathy
[60]. Additionally, studies on human samples have shown
de novo expression of ACE2 in the glomerular endothelium
and mesangial cells of diabetic patients [61]; however, this
expression was not seen in type 2 diabetic renal biopsies
[57]. One study carried out by taking biopsies of twenty
type 2 diabetic patients and twenty healthy donors showed
decreased ACE2 and increased ACE in tubulointerstitium
and glomeruli in the diabetic patients with nephropathy
indicating a pathologically important balance between the
two enzymes [62]. The hypothesis that kidney disease and
the pathogenesis of diabetes are mediated by an upregulation
of ACE and a downregulation of ACE2 was originally
suggested by Mizuiri et al. [62].
As in the heart, loss of ACE2 in the kidneys is again
associated with increased susceptibility to injury. ACE2-
knockout mice have been shown to have enhanced sus-
ceptibility to glomerulosclerosis, coupled with increased
collagen and ﬁbronectin deposition [63]. Filtration dys-
function, evidenced by urinary albumin, was pronounced
in the male mice whereas the female mice appeared to be
protected. Pharmacological inhibition of ACE2, by MLN-
4760, has been shown to have similar eﬀects, increasing
urinary albumin and mesangial cell expansion and vascular
thickness, in both type 1 and type 2 diabetic models [58,
64]. All these studies attributed the pathology seen when
ACE2 is lost to increases in levels of Ang II [58, 63]. In
order to further conﬁrm the renoprotective role of ACE2,
Akita mice (a type 1 model of diabetes) were crossed with
ACE2-knockout mice and kidney function observed. This
model showed an increase in urinary albumin, glomerular
basement membrane thickness, ﬁbronectin, and smooth
muscle α-actin compared to diabetic mice expressing ACE2
[35]. Surprisingly they did not see any change in Ang II
in ACE2-knockouts, or in the diabetic model; despite this,
they did show that use of an Ang II receptor blocker was
able to attenuate some of the markers of glomerular injury
and urinary albumin seen in the ACE2 knockout diabetic
mice. Conversely, ACE2 deletion disrupted the beneﬁts of
ACE inhibition on diabetic nephropathy in streptozotocin-
induced diabetes [65] suggesting that ACE inhibition may
enhance ACE2 activity. Interestingly, in the same diabetic
model, Ang-(1-7) infusion resulted in pronounced renal
injury [66]. This may not be as contradictory as it ﬁrst
appears as they also saw a downregulation in the MAS
receptor, the proposed receptor for Ang-(1-7) [67]. These
current ﬁndings suggest that ACE2 may participate in a
compensatory mechanism in the diabetic kidney prior to the
onset of diabetic nephropathy.
More direct involvement of ACE2 in diabetes, through
its pancreatic expression, has been investigated [68]. ACE2
expression is elevated in the islets of type 2 diabetic rats,
which correlates with an increase in ACE, collagen IV,
and TGF-β1l e v e l s[ 68]. ACE2-null mice have signiﬁcantly
increased fasting blood glucose compared to their wild-type
littermates [69]. No direct role for ACE2 in the pancreas has
yet been identiﬁed; in contrast its homologue collectrin is
heavily implicated in insulin exocytosis. When discovered,
collectrin excited interest due to its high homology to
the cytoplasmic tail of ACE2 [70]. SiRNA knockdown of
collectrin results in a reduction of insulin exocytosis in
insulin-secreting INS-1 cells [71]. In vivo, overexpression of
collectrinledtosigniﬁcantincreasesininsulinsecretion[71].
Collectrin was implicated in the insulin secretory pathway
throughanassociationbetweencollectrinandsnapin,partof
the SNARE complex [70–72]. However, collectrin-knockout
mice revealed no diﬀerence in insulin secretion from wild-
type, only a decrease in insulin sensitivity [73].
ACE2 is not only homologous to ACE but is a chimaera
of ACE, with which it has close homology in the catalytic
domains of the N-terminus, and of collectrin, which closely
resembles the transmembrane and intracellular C-terminal
domains of ACE2 (Figure 2). Collectrin was ﬁrst identiﬁed
as an unknown protein upregulated in a model of partial
nephrectomy, its function remaining elusive for four years
until crystals of tyrosine and phenylalanine were detected
in the urine of collectrin-null mice [74]. Further investi-
gation revealed that the levels of the neutral amino acid
transporter, B0AT1, which reached the plasma membrane
weresigniﬁcantlydecreasedincollectrin-nullmice[75].This
suggested that collectrin may act as a molecular chaperone
for B0AT1 in the kidney, implicating ACE2 in a similar
role, because of their close homology. An elegant set of
studies subsequently revealed that ACE2 did in fact act as the
molecular chaperone for B0AT1 in the small intestine, where
collectrin is not expressed. This interaction was shown to
underliethepathologyoftheaminoaciduriaseeninHartnup
disorder. Hartnup disorder is caused by a mutation on the
outer edge of B0AT1 resulting in its failure to reach the
plasma membrane [76]. It was revealed that this mutation
disrupts the ACE2/B0AT1 complex and therefore prevents
ACE2 from acting as a molecular chaperone delivering the
transporter to the intestinal brush border membrane.
Outside the cardiovascular system another noncatalytic
function of ACE2 had previously been shown. In 2003 a new
disease termed “severe acute respiratory syndrome (SARS)”
caused by a novel coronavirus (SARS-CoV) spread quickly6 International Journal of Hypertension
around the world, causing more than 800 deaths. ACE2 was
identiﬁed as the receptor for SARS virus in vitro [77, 78]
and also acts as receptor for the NL63 virus. Soon after,
studiesconﬁrmedthatACE2wasessentialforSARSinfection
in vivo using ACE2-knockout mice [79]. Concurrently it
was discovered that ACE2 protects murine lungs from
severe acute injury [80] and subsequently that SARS-CoV
infections and the SARS spike protein itself downregulate
ACE2 expression (Figure 3)[ 81].
5. ACE2 Regulation
5.1.TranscriptionalRegulationofACE2. Asmentionedabove
there is circumstantial but not entirely consistent evidence
in the literature that ACE and ACE2 are coregulated. In
human hypertensive patients, ACE2 levels are lower in both
kidneyandheartcomparedtonormotensive volunteers[82].
A growing body of in vitro evidence suggests that this
decrease is mediated at least in part by Ang II [82–84]. The
proposed mechanism for this involves AT1R signalling via
ERK/p38 MAP [82] and/or by elevated ERK1/2 and JNK
phosphorylation [85]. Furthermore, administration of an
AT1R blocker has been shown to result in an increase in
ACE2 levels [84, 86]. As such there is linked regulation of
both ACE2 and ACE, as the catalytic product of ACE, Ang II,
regulates ACE2. However, the role Ang II plays in regulating
ACE2 is not yet fully elucidated; despite decreasing ACE2
expression in response to Ang II in most models there is
evidence of Ang II-mediated increases in ACE2 in hepatic
stellate cells [87].
Relatively little is known about the detailed transcrip-
tional regulation of ACE2. Although angiotensin peptides,
as well as other peptide and steroid hormones, appear to
modulate its expression, few studies have been done on other
factorsthatmaycontrolitsregulation,suchashormonesand
oxygen levels. For example, although hypoxia decreases the
transcriptionofACE2,furtherinvestigationhasrevealedthat
hypoxia-induced HIF-1α increases ACE expression which, in
turn, leads to an increased concentration of Ang II. It is this
Ang II that then mediates a decrease in ACE2 [88]. Ang-(1-
7) has also been shown to aﬀect ACE2 expression: cardiac
and renal ACE2 were decreased in both hypertensive and
normotensive rat models in response to Ang-(1-7) infusion
although no eﬀects on blood pressure were demonstrated
and no mechanism of action was proposed [89].
Administration of aldosterone or endothelin-1 to rat
myocytes has also been shown to downregulate ACE2 mRNA
levels [90]. Micromolar concentrations of aldosterone were
shown to decrease ACE2 mRNA expression signiﬁcantly in
the myocytes of hormone-infused rats although, in contrast
to other models, no change in ACE2 mRNA levels were
seen when these rats were infused with Ang II [83]. When
treated with endothelin-1, myocytes isolated from neonatal
rats decrease ACE2 expression via ERK1/ERK2 signalling, a
decrease that was blocked by cotreatment with Ang-(1-7)
[90].TheeﬀectofoestrogenonACE2expressionhasrecently
also been explored in light of clinical evidence which has
established that hormone replacement therapy is protective
against cardiovascular disease. Treating rats with oestrogen
was shown to reduce cardiac remodelling and interstitial
ﬁbrosis [91]. Previous in vitro studies had shown that
oestradiol (E2) treatment was protective against Ang II-
induced ﬁbroblast proliferation [92]. The beneﬁcial eﬀects
of oestrogen were coupled with a dose-dependent increase in
ACE2 but no signiﬁcant change in blood pressure was seen
and no protective mechanism proposed [91].
Components of the RAS are also expressed in adipose
tissue [93]. A high-fat diet has been shown to increase ACE2
mRNA levels in mouse adipocytes both in vivo and in vitro
[94] although these changes were not evident in the adipose
tissues of mice with heart failure. Tissue culture models of
adipose diﬀerentiation have shown that the increase in ACE2
mRNA over time was accompanied by an increase in ADAM
17 and no increase in ACE2 activity [94]. Thus the activity
levels of ACE2 remain constant via coregulation with ADAM
17, which cleaves ACE2 at the cell membrane. An increase in
ACE2 expression has been reported in adipose tissue when
rats were fed a high-sucrose diet, although in preliminary
form only [95].
The eﬀects of all-trans-retinoic acid have been investi-
gated on ACE2 expression revealing an increase in ACE2
mRNA levels and reportedly in protein [53]. A decrease in
blood pressure in the treated rats was also seen, which was
attributed to the increased ACE2 levels.
5.2. Posttranslational Regulation of ACE2. ACE2 expression
is not only subject to posttranslational modiﬁcations, such
as glycosylation and phosphorylation, but also subject to
posttranslational regulation, when released from the cell
membrane by shedding through the action of ADAM 17 as
described above [21, 96, 97]. Cleavage of ACE2 occurs at
the juxtamembrane region. Short peptide mimics around
the likely cleavage site region are hydrolysed by recombinant
ADAM 17 at an Arg-Ser bond (corresponding to Arg708 and
Ser709 in ACE2), in a sequence-dependent manner [93, 94].
However, mutation of these critical cleavage residues in a
cell-based system failed to inhibit shedding suggesting that
the speciﬁcity of ADAM 17 is topographically determined,
rather than sequence dependent [97, 98]. The function
(if any) of the catalytically active soluble, shed form is
unknown, although for some other proteins, for example,
the amyloid precursor protein and acetylcholinesterase, the
released protein acts as a ligand for stimulating cell-cell
interactions. The retention of ACE2 on the cell membrane is
regulated by calmodulin binding [99]. Inhibition of calmod-
ulin binding increases the cellular release of ACE2. Elevated
levels of shed ACE2 have been associated with increased
myocardial dysfunction [100]. The catalytic activity of any
shed ACE2 may be masked by the presence of an endogenous
inhibitor of ACE2 in the plasma, which currently remains
uncharacterised [101].
As previously mentioned SARS virus downregulates
cellular expression of ACE2 [102]. Binding of the SARS
spike protein induced ADAM-17-dependent shedding of
ACE2 N-terminal domain [103]( Figure 3). This shed-
ding has been reported by diﬀerent groups to be both
essential for viral replication [104] and unnecessary [97].International Journal of Hypertension 7
Figure 3: ACE2 acts as the host cell receptor for SARS-CoV, by binding to the spike protein on the viral capsid. Binding to ACE2 stimulates
clathrin-dependent endocytosis of both ACE2 and the SARS-CoV, which is essential for viral infection. Binding of the spike protein to ACE2
induces ADAM 17 activity, thereby reducing the amount of ACE2expressed on the cell surface. Treatment with soluble ACE-2or anti-ACE-2
antibodies disrupts the interaction between virus and receptor.
The SARS virus undergoes clathrin-dependent endocytosis
upon receptor binding; this process internalises both the
SARS virus and its receptor further clearing ACE2 from the
cell membrane (Figure 3) and hence allowing enhanced (and
damaging) reactivity towards circulating Ang II. In contrast
to ectodomain shedding, the cytoplasmic domain of ACE2
appears to play no role in the regulation of internalisation
[105].
6. UnansweredQuestions
Currently the most pertinent of all questions about ACE2
is whether it is going to be a useful therapeutic target, and
so far all data suggest that increased expression would be
beneﬁcial in a number of diseases. Until now an increase in
the level of ACE2 has been achieved by viral delivery [106],
application of allosteric activators of ACE2 catalysis [107],
or administration of human recombinant ACE2 [108]. Aside
fromitseﬀectsonhypertension[22–25],viraloverexpression
of ACE2 has shown reduced collagen production in cultured
ﬁbroblasts [106] as well as inhibition of Ang-II-induced
ﬁbrosis and hypertrophy in vivo [109], stabilisation of
atherosclerotic plaques [110], and renoprotection [24]. Viral
delivery of ACE2 after induction of myocardial infarction
is protective, reducing the adverse cardiac remodelling and
ﬁbrosis [111, 112]. Similar antiﬁbrotic eﬀects have been seen
with an ACE2 activator [113, 114] along with attenuation
of Ang-II-induced thrombus in hypertensive rats [115]a n d
a modest reduction in the blood pressure of spontaneously
hypertensive rats [107]. Over the past 18 months a number
of studies have been carried out examining the eﬀect of
recombinant human ACE2 on a range of disease conditions.
To date, administration of ACE2 to mouse models of Ang-II-
induced diseases has been shown to reverse the pathological
eﬀects of Ang II in diabetic nephropathy [116], heart disease
[117], renal oxidative stress [118]a sw e l la sr e v e r s a lo f
Ang-II-induced hypertension [108]. Interestingly, infusion
of ACE2 does not appear to have any eﬀect on nondisease
states or on the basal level of Ang II in wild-type mice
or ACE2-knockout mice, making it a potentially valuable
therapeutic.
More fundamental questions about the cellular biology
of ACE2 remain. As is evident from this paper, questions
need answering about underlying mechanisms of ACE2
regulation, which could help clarify our understanding of
the RAS as a whole, for example, are there antagonistic tran-
scription factors regulating ACE and ACE2? Are components
of the RAS co-ordinately regulated and by which signalling
pathways?DomicroRNAsregulatetheRAScoordinately?Do
cytokines modify the expression of ACE2? What posttransla-
tional changes apart from shedding regulate ACE2 including
phosphorylation and ubiquitination?
Some analogies are provided by the regulation of ACE.
ACE is known to signal through phosphorylation of its
cytoplasmic tail modulating its own retention on the cell
membrane [119, 120] and also to mediate transmembrane
signalling, increasing its own transcription in response to
ACE inhibitors [121, 122]. Exogenous ACE has been shown
to have transcriptional eﬀects independent of its catalytic
activity when VSMC and endothelial cells are treated with
ACE [123, 124]. Does the cytoplasmic tail of ACE2, despite
sharingnohomologywithACE,havesimilarsignallingprop-
erties? Both ACE and ACE2 are shed from the membrane to
release their ectodomains. The fate of these ectodomains is
unknown and it may be a mechanism of rapid clearance, or
perhaps these ectodomains are endocytosed and traﬃcked
to the nucleus, where they elicit transcriptional changes, as
has been shown with exogenous ACE [124]. For that matter
the destiny of the retained cytoplasmic sections of these8 International Journal of Hypertension
proteins is not known. The intracellular domains of other
shed proteins, such as APP and Notch, are released by γ-
secretase cleavage, after initial ADAM ectodomain cleavage,
a process referred to as intramembrane proteolysis [125].
The intracellular domains of both APP and Notch travel
to the nucleus, stabilised by chaperones, where they elicit
transcriptional changes [126]. Perhaps a similar fate awaits
the ACE intracellular domain, if generated.
Novel roles for ACE2 may yet remain to be discovered
and a new twist to the ACE2 story has emerged with
the discovery of autoantibodies targeting ACE2 in the sera
of patients with connective tissue diseases [127]. This,
coupled with results showing that administration of an
ACE2 inhibitor improved the pathology of inﬂammatory
bowel disease [12], suggests that inhibition of ACE2 may be
beneﬁcial in inﬂammatory diseases such as arthritis.
7. Summary
The diversity of the roles of ACE2 continues to surprise
those in the ﬁeld. Given the apparent success of recombinant
human ACE2 in animal models, ACE2 could be a valuable
therapeutic. However, here it is worth noting that so far the
only disease model recombinant ACE2 has shown success in
is type 1 diabetes. All other studies have, as yet, only shown
that ACE2 reverses the eﬀects of exogenous Ang II infusion.
Until work is done on hypertensive-prone models, as with
viral delivery and ACE2 activator-mediated induction, it
is hard to judge the clinical relevance of this treatment.
Although no immune response to recombinant ACE2 or the
viral delivery systems has been reported upon infusion into
rodents, this is always a concern with such strategies. Given
these caveats perhaps a priority focus for future research
shouldbeupregulationofendogenousACE2geneexpression
or catalytic activity. As highlighted in this paper, more work
is required to determine how the diverse roles of ACE2
interlinkinordertoallowchronicmodulationofACE2levels
to proceed with conﬁdence.
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